Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
01:27am, Wednesday, 22'nd Apr 2026
NEW YORK, April 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and De
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
09:30pm, Tuesday, 21'st Apr 2026
SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunothera
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 an
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
03:59pm, Tuesday, 21'st Apr 2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) and certa
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Tuesday, 21'st Apr 2026
New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed again
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
11:41am, Tuesday, 21'st Apr 2026
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the cla
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February
Why Nektar Therapeutics Stock Rocked it Today
07:13pm, Monday, 20'th Apr 2026
The successful phase 2b trial followed a previous study that was affected by apparent enrollment errors. The company plans to advance the drug through its pipeline.
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development
04:17pm, Monday, 20'th Apr 2026
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development
Nektar Therapeutics Announces Proposed Public Offering
04:01pm, Monday, 20'th Apr 2026
SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunothera
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in Nektar Therapeutics (NASDAQ: NKTR) during the period from February 26, 2025 through December 15, 2025 may wish
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript
